Acrivon Therapeutics, Inc. (ACRV) - Dilution Analysis

10-Q filing | 38.7M shares outstanding

10-K filing | 38.5M shares outstanding

10-Q filing | 31.6M shares outstanding

10-Q filing | 31.5M shares outstanding

10-Q filing | 31.4M shares outstanding

10-K filing | 33.8M shares outstanding

10-Q filing | 31.1M shares outstanding

10-Q filing | 31.0M shares outstanding

10-Q filing | 30.9M shares outstanding

S-3 filing: Acrivon Therapeutics, Inc. is offering up to 15,295,000 shares of common stock by selling stockholders via resale.

8-K filing: Acrivon Therapeutics, Inc. entered into a securities purchase agreement for a private placement with institutional and accredited investors to issue and sell 8,235,000 shares of common stock at $8.50 per share and pre-funded warrants to purchase up to 7,060,000 shares of common stock at $8.499 per Pre-Funded Warrant, with gross proceeds of approximately $130 million. ($129.99M proceeds)

10-K filing | 22.1M shares outstanding

S-3 filing: Acrivon Therapeutics, Inc. files an S-3 form to offer and sell up to an aggregate of $300,000,000 of common stock, preferred stock, and debt securities from time to time in one or more offerings.

10-Q filing | 22.1M shares outstanding

10-Q filing | 22.0M shares outstanding

10-Q filing | 21.9M shares outstanding

10-K filing | 21.9M shares outstanding

10-Q filing | 20.9M shares outstanding

S-1/A filing: This S-1/A filing describes the voting rights, liquidation preferences, and other rights associated with the company's common stock. It also discusses the lock-up agreements, potential market stabilization activities by underwriters, and indemnification agreements related to the offering of common stock.

S-1 filing: The filing relates to the potential issuance of Common Stock, Options or Convertible Securities under various circumstances, including dividends, stock splits, employee compensation, debt financing, and strategic partnerships.